公开(公告)号：US20230149405A1

公开(公告)日：2023-05-18

申请号：US17916904

申请日：2021-04-07

申请人： LABORATOIRES C.T.R.S. ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  FONDATION IMAGINE ,  UNIVERSITÉ PARIS CITÉ ,  UNIVERSITE PARIS-SACLAY

发明人： Christine BODEMER ,  Céline GRECO ,  Claude BOUCHEIX ,  Jean-Pascal CONDUZORGUES ,  Joel SCHLATTER ,  Salvatore CISTERNINO

IPC分类号： A61K31/517 ,  A61K9/00 ,  A61K9/107 ,  A61K9/08 ,  A61P17/02 ,  A61K47/10 ,  A61K47/40 ,  A61K47/32 ,  A61K47/38

CPC分类号： A61K31/517 ,  A61K9/0014 ,  A61K9/107 ,  A61K9/08 ,  A61P17/02 ,  A61K47/10 ,  A61K47/40 ,  A61K47/32 ,  A61K47/38

摘要： A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.

公开(公告)号：US20220202820A1

公开(公告)日：2022-06-30

申请号：US17604109

申请日：2020-04-15

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  FONDATION IMAGINE ,  UNIVERSITÉ DE PARIS ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)

发明人： Christine BODEMER ,  Patrick DELMAS ,  Céline GRECO

IPC分类号： A61K31/519 ,  A61K31/407 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/553 ,  A61P29/02

摘要： An increasing body of evidence suggests that Nav1.7 encoded by SCN9A gene may play a key role in various pain states, including acute, inflammatory and/or neuropathic pain. The inventors now report an efficient treatment for severe cases of primary erythromelagia linked to a specific SCN9A mutation. In particular the inventors demonstrated that the inhibition of JAK2 produces a rightward shift in the voltage dependent activation of mutant Nav1.7 channels, thereby normalizing the function of mutant Nav1.7 channels. On this basis, the inventors treated a patient suffering from PE with very severe refractory pain with a JAK2 inhibitor (ruxolitinib) and showed the therapy leads to considerable reduction of pain. Accordingly, the present invention relates to the use of JAK inhibitors for the treatment of painful conditions involving Nav1.7 channels.

公开(公告)号：US20210393632A1

公开(公告)日：2021-12-23

申请号：US17281745

申请日：2019-10-03

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Assistance Publique-Hôpitaux de Paris (APHP) ,  Université de Paris ,  Fondation Imagine ,  Université Paris-Sud

发明人： Christine BODEMER ,  Céline GRECO ,  Claude BOUCHEIX

IPC分类号： A61K31/517 ,  A61K31/675 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4706 ,  A61P17/12

摘要： Olmsted syndrome (OS) is a rare genodermatosis classically characterized by the combination of bilateral mutilating transgredient palmoplantar keratoderma (PPK) and periorificial keratotic plaques. The inventors obtained remarkable results with a treatment with a EGFR inhibitor (e.g. erlotinib) in 3 patients with Olmsted Syndrome and erythemalgia linked to different TRPV3 mutations. In less than 3 months, the drug induced a complete disappearance of the hyperkeratosis and the pain. Anorexia and insomnia disappeared with an improvement of the growth. Accordingly, the present invention relates to the use of EGFR inhibitors for the keratodermas.